AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster
Portfolio Pulse from
UBS has reaffirmed its 'buy' rating on AstraZeneca, with a 12-month price target of 14,200p, due to the potential of its experimental blood pressure drug, baxdrostat. This drug is part of a new class of treatments called aldosterone synthase inhibitors.
March 12, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has reaffirmed its 'buy' rating on AstraZeneca, with a 12-month price target of 14,200p, due to the potential of its experimental blood pressure drug, baxdrostat.
The reaffirmation of a 'buy' rating by UBS and a specific price target suggests confidence in AstraZeneca's future performance, particularly due to the potential of its new drug, baxdrostat. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100